Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | SRC | P12931 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.52 |
| ▸ | HPGD | P15428 | 4/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 5/20 | 0.52 |
| ▸ | GAA | P10253 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.52 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.52 |
| ▸ | PRNP | P04156 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30099730 | 1.00 | ALDH1A1 (0.56) | ALDH1A1KMT2ALMNASMN1; SMN2EGFR | |
| SCHEMBL9216581 | 0.82 | KDM4E (0.64) | ALDH1A1KMT2ALMNASMN1; SMN2KDM4E | |
| SCHEMBL29891520 | 0.81 | KDM4E (0.64) | ALDH1A1KMT2ALMNASMN1; SMN2KDM4E | |
| SCHEMBL23411350 | 0.81 | KDM4E (0.64) | ALDH1A1KMT2ALMNASMN1; SMN2KDM4E | |
| SCHEMBL29891965 | 0.81 | EGFR (0.55) | ALDH1A1KMT2ALMNASMN1; SMN2EGFR | |
| SCHEMBL569008 | 0.81 | EGFR (0.55) | ALDH1A1KMT2ALMNASMN1; SMN2EGFR | |
| SCHEMBL23410160 | 0.80 | LMNA (0.41) | KMT2ALMNASMN1; SMN2SRCKDM4E | |
| SCHEMBL29891687 | 0.80 | LMNA (0.41) | KMT2ALMNASMN1; SMN2SRCKDM4E | |
| SCHEMBL23410902 | 0.80 | MAPT (0.41) | ALDH1A1KMT2ALMNAEGFRSRC | |
| SCHEMBL29892950 | 0.80 | MAPT (0.41) | ALDH1A1KMT2ALMNAEGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4081513-B1 | SUBSTITUTED QUINOLINONYL PIPERAZINE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20230061608-A1 | SUBSTITUTED QUINOLINONYL PIPERAZINE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-03-02 | — | — | US | disclosed |
| US-20230061608-A1 | SUBSTITUTED QUINOLINONYL PIPERAZINE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-03-02 | — | — | US | disclosed |
| CN-115103841-A | Substituted quinolinonyl piperazine compounds useful as T cell activators | 百时美施贵宝公司 | 2022-09-23 | — | — | CN | disclosed |
| WO-2021133748-A1 | SUBSTITUTED QUINOLINONYL PIPERAZINE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021133748-A1 | SUBSTITUTED QUINOLINONYL PIPERAZINE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-01 | — | — | WO | disclosed |
| EP-3354640-A2 | MIF INHIBITORS AND THEIR USES | Innovimmune Biotherapeutics, Inc. (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-3354640-A2 | MIF INHIBITORS AND THEIR USES | Innovimmune Biotherapeutics, Inc. (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-2696682-B1 | MIF INHIBITORS AND THEIR USES | INNOVIMMUNE BIOTHERAPEUTICS INC (US) | 2018-03-21 | — | — | EP | disclosed |
| EP-2696682-B1 | MIF INHIBITORS AND THEIR USES | INNOVIMMUNE BIOTHERAPEUTICS INC (US) | 2018-03-21 | — | — | EP | disclosed |
| US-9050334-B2 | MIF inhibitors and their uses | INNOV88 LLC (US) | 2015-06-09 | — | — | US | disclosed |
| US-20150065480-A1 | MIF INHIBITORS AND THEIR USES | INNOVIMMUNE BIOTHERAPEUTICS, INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150065480-A1 | MIF INHIBITORS AND THEIR USES | INNOVIMMUNE BIOTHERAPEUTICS, INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150065480-A1 | MIF INHIBITORS AND THEIR USES | INNOVIMMUNE BIOTHERAPEUTICS, INC. (US) | 2015-03-05 | — | — | US | disclosed |
| WO-2012142498-A2 | MIF INHIBITORS AND THEIR USES | INNOVIMMUNE BIOTHERAPEUTICS, INC. (US) | 2012-10-18 | — | — | WO | disclosed |
| US-20120035150-A1 | MIF INHIBITORS AND THEIR USES | INNOV88 LLC | 2012-02-09 | — | — | US | disclosed |
| US-20120035150-A1 | MIF INHIBITORS AND THEIR USES | INNOV88 LLC | 2012-02-09 | — | — | US | disclosed |
| US-20120035150-A1 | MIF INHIBITORS AND THEIR USES | INNOV88 LLC | 2012-02-09 | — | — | US | disclosed |
| WO-2012009649-A1 | MIF INHIBITORS AND THEIR USES | GAWECO ANDERSON (US) | 2012-01-19 | — | — | WO | disclosed |
| US-20090060866-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035150-A1 | MIF INHIBITORS AND THEIR USES | MIF, SERPINB1, HMGB2 | ALDH1A1 790/4885KMT2A 3622/4885LMNA 3162/4885 |
| US-20230061608-A1 | SUBSTITUTED QUINOLINONYL PIPERAZINE COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | ALDH1A1 3975/4885KMT2A 1558/4885LMNA 3271/4885 |
| US-20150065480-A1 | MIF INHIBITORS AND THEIR USES | MIF, SERPINB1, HMGB2 | ALDH1A1 790/4885KMT2A 3622/4885LMNA 3162/4885 |
| US-20090060866-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II | POLR2E, POLR2H, POLR2A | ALDH1A1 1531/4885KMT2A 2571/4885LMNA 3922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.